Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ARG1 | P05089 | 2/20 | 0.37 |
| ▸ | ARG2 | P78540 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337669 | 0.82 | — | — | |
| SCHEMBL28577949 | 0.81 | MEN1 (0.65) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL8240842 | 0.81 | MEN1 (0.65) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL26670499 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL18952379 | 0.79 | MEN1 (0.44) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL6238533 | 0.79 | ARG1 (0.44) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL6235982 | 0.79 | ARG1 (0.44) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| Hydrochloric Acid SCHEMBL31604903 | 0.78 | MEN1 (0.40) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL7086649 | 0.77 | ALDH1A1 (0.73) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| Hydrochloric Acid SCHEMBL14631979 | 0.77 | MEN1 (0.50) | MEN1ALDH1A1CYP1A2THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | MEN1 4752/4885ALDH1A1 2124/4885CYP1A2 1541/4885 |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, PLK2, PNCK | MEN1 3885/4885ALDH1A1 2848/4885CYP1A2 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.